72 304

Cited 0 times in

Clinical Efficacy and Tolerance of 1% Nadifloxacin Cream in the Treatment of Mild to Moderate Acne Vulgaris in South Korea

Other Title
경증 및 중등도의 한국인 여드름 환자에서 1% Nadifloxacin 크림(Nadixa(R))의 유효성 및 안전성 평가
최, 원준; 김, 광중; 김, 낙인; 계, 영철; 서, 대헌; 이, 주흥; 김, 명남; 이, 은소; 이, 주희; 노, 영석
Korean journal of dermatology, 48(8):665-671, 2010
Journal Title
Korean journal of dermatology; 대한피부과학회지
Background: Antimicrobials have been a mainstay of inflammatory acne treatment for more than 30 years. However, antibiotic-resistant propionibacteria had been isolated with increased frequency, and associated with failure to respond to antibiotic therapy.

Objective: The aim of this study was to investigate the clinical efficacy and tolerance of 1% nadifloxacin cream.

Methods: In the final analysis, 197 patients with mild to moderate facial acne vulgaris were enrolled. The patients were instructed to apply 1% nadifloxacin cream twice daily to the affected skin after washing the face. Following 2 and 4 weeks of treatment, patients were observed for clinical response: number of the acne lesions, Korea acne grading system (KAGS), global improvement, and occurrence of adverse reactions.

Results: During 4 weeks of treatment, nadifloxacin caused significant reduction in the number of inflamed papulo-pustular lesions and open/closed comedones. In addition, significant reduction of KAGS was observed. About 96% of patients showed clinical improvement in the overall evaluation of the therapeutic effect by physicians. All reported adverse events were mild.

Conclusion: This study shows that 1% nadifloxacin cream can be an effective and safe treatment for mild to moderate acne vulgaris.
1% nadifloxacin creamAcneTreatment
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Dermatology
AJOU Authors
이, 은소
Files in This Item:
fulltext not available.txtDownload
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.